Médecine

Paramédical

Autres domaines


Suscribirse

A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study - 19/12/20

Doi : 10.1016/j.biopha.2020.111037 
Keng-Chang Tsai a, b , Yi-Chia Huang c , Chia-Ching Liaw a , Chia-I Tsai d , Chun-Tang Chiou a , Chien-Jung Lin c , Wen-Chi Wei a , Sunny Jui-Shan Lin c , Yu-Hwei Tseng a , Kuo-Ming Yeh e , Yi-Ling Lin f , Jia-Tsrong Jan g , Jian-Jong Liang f , Chun-Che Liao f , Wen-Fei Chiou a , Yao-Haur Kuo a , Shen-Ming Lee h , Ming-Yung Lee i , Yi-Chang Su a, j,
a National Research Institute of Chinese Medicine, Ministry of Health and Welfare, No.155-1, Section 2, Linong Street, Beitou District, Taipei 11221, Taiwan 
b Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, No. 250 Wu-Xing Street, Taipei 11031, Taiwan 
c Department of Chinese Medicine, Tri-Service General Hospital, National Defense Medical Center, No.325, Section 2, Chenggong Road, Neihu District, Taipei 11490, Taiwan 
d Department of Traditional Chinese Medicine, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Section 4, Seatwen District, Taichung 407204, Taiwan 
e Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Section 2, Chenggong Road, Neihu District, Taipei 11490, Taiwan 
f Institute of Biomedical Sciences, Academia Sinica, No. 128, Section 2, Academia Road, Nankang District, Taipei 11529, Taiwan 
g Genomic Research Center, Academia Sinica, No. 128, Section 2, Academia Road, Nankang District, Taipei, 11529, Taiwan 
h Department of Statistic, Feng Chia University, No. 100, Wenhwa Road, Seatwen District, Taichung 40724, Taiwan 
i Department of Data Science and Big Data Analytics, Providence University, Taichung, No. 200, Section 7, Taiwan Boulevard, Shalu District, Taichung 43301, Taiwan 
j School of Chinese Medicine, College of Chinese Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung 40402, Taiwan 

Corresponding author at: National Research Institute of Chinese Medicine, Ministry of Health and Welfare, No. 155-1, Sec. 2, Linong Street, Beitou District, Taipei 11221, Taiwan.National Research Institute of Chinese MedicineMinistry of Health and WelfareNo. 155-1, Sec. 2, Linong StreetBeitou DistrictTaipei11221Taiwan

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

A herb-based formula delivers positive clinical outcomes on COVID-19 patients.
The formula inhibits SARS-CoV-2 pathogenesis in anti-viral & -inflammatory assays.
Real-world-evidence offers insights to inform drug development.
Bed-to-bench approach shortens the time required for finding effective therapeutics.

El texto completo de este artículo está disponible en PDF.

Abstract

COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19.

El texto completo de este artículo está disponible en PDF.

Keywords : SARS-CoV-2, Traditional Chinese medicine, NRICM101, Spike protein, 3CL protease, Cytokine storm


Esquema


© 2021  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 133

Artículo 111037- janvier 2021 Regresar al número
Artículo precedente Artículo precedente
  • Preconditioning by ultra-low dose of tramadol reduces the severity of tramadol-induced seizure: Contribution of glutamate receptors
  • Neda Valian, Marziyeh Sorayya, Sareh Asadi, Fatemeh Sherafati, Ali Ershad, Sara Savaheli, Abolhassan Ahmadiani
| Artículo siguiente Artículo siguiente
  • Aster tataricus alleviates constipation by antagonizing the binding of acetylcholine to muscarinic receptor and inhibiting Ca2+ influx
  • Hao Wu, Yijun Chen, Beibei Huang, Yingting Yu, Shujun Zhao, Jie Liu, Zhixin Jia, Hongbin Xiao

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.